Comparison of a new Light Diagnostics™ and the CMV Brite™ to an in-house developed human cytomegalovirus antigenemia assay

Journal of Clinical Virology

Volumn 43, Issue 1, 2008, Pages 13-17

  Percivalle, Elena ^a   Genini, Emilia ^a   Chiesa, Antonella ^a   Gerna, Giuseppe ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

DNAemia; Human cytomegalovirus; Immunocompromised patients; PCR; pp65 antigenemia

Indexed keywords

ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; CYTOMEGALOVIRUS INFECTION; CYTOPLASM; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOCOMPROMISED PATIENT; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOCOMPROMISED HOST; LEUKOCYTES; PHOSPHOPROTEINS; SENSITIVITY AND SPECIFICITY; VIRAL MATRIX PROTEINS; VIREMIA;

EID: 49749147824     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2008.03.028     Document Type: Article

References (22)

1. Baldanti F., Lurain N., Gerna G., and Clinical. biological aspects of human cytomegalovirus resistance to antiviral drugs. Hum Immunol 65 (2004) 403-409
2. Boeckh M., Gooley T.A., Myerson D., Cunningham T., Schoch G., and Bowden R.A. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 88 (1996) 4063-4071
3. Egan J.J., Lomax J., Barber L., Lok S.S., Martyszczuk R., Yonan N., et al. Preemptive treatment for the prevention of cytomegalovirus disease: in lung and heart transplant recipients. Transplantation 65 (1998) 747-752
4. Gerna G., Zipeto D., Parea M., Revello M.G., Silini E., Percivalle E., et al. Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia and DNAemia. J Infect Dis 164 (1991) 488-498
5. Gerna G., Revello M.G., Percivalle E., and Morini F. Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol 30 (1992) 1232-1237
6. Gerna G., Percivalle E., Torsellini M., and Revello M.G. Standardization of the human cytomegalovirus antigenemia assay by means of in vitro generated pp65-positive peripheral blood polymorphonuclear leukocytes. J Clin Microbiol 36 (1998) 3585-3589
7. Gerna G., Zavattoni M., Percivalle E., Grossi P., Torsellini M., and Revello M.G. Rising levels of human cytomegalovirus (HCMV) antigenemia during initial antiviral treatment of solid-organ transplant recipients with primary HCMV infection. J Clin Microbiol 36 (1998) 1113-1116
8. Gerna G., Lilleri D., Baldanti F., Torsellini M., Giorgiani G., Zecca M., et al. Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial. Blood 101 (2003) 5053-5060
9. Gerna G., Baldanti F., Lilleri D., Parea M., Torsellini M., Castiglioni B., et al. Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial. Transplantation 75 (2003) 1012-1019
10. Gerna G., Sarasini A., Lilleri D., Percivalle E., Torsellini M., Baldanti F., et al. In vitro model for the study of the dissociation of increasing antigenemia and decreasing DNAemia and viremia during treatment of human cytomegalovirus infection with ganciclovir in transplant recipients. J Infect Dis 188 (2003) 1639-1647
11. Gerna G., Lilleri D., Zecca M., Alessandrino E.P., Baldanti F., Revello M.G., et al. Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Haematologica 90 (2005) 526-533
12. Gerna G., Baldanti F., Torsellini M., Minoli L., Viganò M., Oggionni T., et al. Evaluation of human cytomegalovirus DNAemia versus pp65-antigenemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study. Antivir Ther 12 (2007) 63-72
13. Grefte J.M.M., Van der Gun B.T.F., Schmolke S., Van der Giessen M., Van Son W.J., and The T.H. The lower matrix protein pp65 is the principal viral antigen present in peripheral blood leukocytes during an active cytomegalovirus infection. J Gen Virol 73 (1992) 2923-2932
14. Kusne S., Shapiro R., and Fung J. Prevention and treatment of cytomegalovirus infection in organ transplant recipients. Transpl Infect Dis 1 (1999) 187-203
15. Lilleri D., Gerna G., Furione M., Bernardo M.E., Giorgiani G., Telli S., et al. Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem cell transplantation compared with qualitative pp65 antigenemia. Blood 110 (2007) 2757-2760
16. Locatelli F., Percivalle E., Comoli P., Maccario R., Zecca M., Giorgiani G., et al. Human cytomegalovirus (HCMV) infection in paediatric patients given allogeneic bone marrow transplantation: role of early antiviral treatment for HCMV antigenaemia on patients' outcome. Br J Haematol 88 (1994) 64-71
17. Merigan T.C., Renlund D.G., Keay S., Bristow M.R., Starnes V., O'Connell J.B., et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 326 (1992) 1182-1186
18. Revello M.G., Zavattoni M., Percivalle E., Grossi P., and Gerna G. Correlation between immunofluorescent detection of human cytomegalovirus immediate early antigens in polymorphonuclear leukocytes and viremia. J Infect Dis 160 (1989) 159-160
19. Revello M.G., Percivalle E., Di Matteo A., Morini F., and Gerna G. Nuclear expression of the lower matrix protein of human cytomegalovirus in peripheral blood leukocytes of immunocompromised viremic patients. J Gen Virol 73 (1992) 437-442
20. Revello M.G., and Gerna G. Diagnosis and management of human cytomegalovirus infection in the mother, fetus and newborn infant. Clin Microbiol Rev 15 (2002) 680-715
21. Van den Berg A.P., Klompmaker I.J., Haagsma E.B., Scholten-Sampson A., Bijleveld C.M.A., Schirm J., et al. Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. J Infect Dis 164 (1991) 265-270
22. Van der Bij W., Schirm J., Torensma R., Van Son W.J., Tegzess A.M., and The T.H. Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. J Clin Microbiol 26 (1988) 2531-2535